Anti-NMDA receptor encephalitis surgery: Difference between revisions
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Anti-NMDA receptor encephalitis}} | {{Anti-NMDA receptor encephalitis}} | ||
{{CMG}} | {{CMG}} AE {{DMakkar}} | ||
==Overview== | ==Overview== | ||
Surgery plays a crucial role in the treatment of anti-NMDA encephalitis when an associated tumor, typically an ovarian teratoma, is present. Tumor removal can improve prognosis, reduce relapse risk, and enhance response to immunotherapy. A multidisciplinary approach is essential for optimal patient management. | |||
==Surgery== | ==Surgery== | ||
*Surgery is primarily considered in the treatment of anti-NMDA encephalitis when there is an associated tumor, most commonly an ovarian teratoma. | |||
*The removal of the tumor is important as it can contribute to the generation of antibodies causing the encephalitis. | |||
*Surgery can improve the patient's overall prognosis and reduce the risk of relapse. | |||
*Surgical removal of the tumor may lead to a more rapid resolution of symptoms and better response to immunotherapy. | |||
However, in cases without an associated tumor, surgery alone is not a standard treatment for anti-NMDA encephalitis, and immunotherapy remains the mainstay of treatment. | |||
*The decision to proceed with surgery is made on a case-by-case basis, taking into consideration various factors such as the presence and type of tumor, the patient's overall health, and the severity of neurological symptoms. | |||
*A multidisciplinary approach involving neurologists, neurosurgeons, and oncologists is crucial to ensure optimal management and outcomes for patients with anti-NMDA encephalitis. | |||
==References== | ==References== | ||
Latest revision as of 17:06, 13 May 2023
|
Anti-NMDA receptor encephalitis Microchapters |
|
Differentiating Anti-NMDA receptor encephalitis from Other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Anti-NMDA receptor encephalitis surgery On the Web |
|
American Roentgen Ray Society Images of Anti-NMDA receptor encephalitis surgery |
|
Directions to Hospitals Treating Anti-NMDA receptor encephalitis |
|
Risk calculators and risk factors for Anti-NMDA receptor encephalitis surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] AE Dheeraj Makkar, M.D.[2]
Overview
Surgery plays a crucial role in the treatment of anti-NMDA encephalitis when an associated tumor, typically an ovarian teratoma, is present. Tumor removal can improve prognosis, reduce relapse risk, and enhance response to immunotherapy. A multidisciplinary approach is essential for optimal patient management.
Surgery
- Surgery is primarily considered in the treatment of anti-NMDA encephalitis when there is an associated tumor, most commonly an ovarian teratoma.
- The removal of the tumor is important as it can contribute to the generation of antibodies causing the encephalitis.
- Surgery can improve the patient's overall prognosis and reduce the risk of relapse.
- Surgical removal of the tumor may lead to a more rapid resolution of symptoms and better response to immunotherapy.
However, in cases without an associated tumor, surgery alone is not a standard treatment for anti-NMDA encephalitis, and immunotherapy remains the mainstay of treatment.
- The decision to proceed with surgery is made on a case-by-case basis, taking into consideration various factors such as the presence and type of tumor, the patient's overall health, and the severity of neurological symptoms.
- A multidisciplinary approach involving neurologists, neurosurgeons, and oncologists is crucial to ensure optimal management and outcomes for patients with anti-NMDA encephalitis.
References
- ↑ Delangle R, Demeret S, Canlorbe G, Chelon L, Belghiti J, Gonthier C; et al. (2020). "Anti-NMDA receptor encephalitis associated with ovarian tumor: the gynecologist point of view". Arch Gynecol Obstet. 302 (2): 315–320. doi:10.1007/s00404-020-05645-9. PMID 32556515 Check
|pmid=value (help).